Last reviewed · How we verify
NCT07408869
A Phase 1b, Open-Label Study Evaluating the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Cizutamig in IgE Mediated Diseases
Phase 1 trial testing Cizutamig in IgE-Mediated Hypersensitivity in 20 participants. Not yet recruiting.
1 December 2026
Quick facts
| Lead sponsor | Candid Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 April 2026 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across Australia |
Drugs / interventions tested
- Cizutamig — full drug profile →
Conditions studied
- IgE-Mediated Hypersensitivity — all drugs for IgE-Mediated Hypersensitivity →
- IgE Mediated Food Allergy — all drugs for IgE Mediated Food Allergy →
- IgE-Mediated Cow Milk Allergy — all drugs for IgE-Mediated Cow Milk Allergy →
Sponsor
Candid Therapeutics — full company profile →
Who can join
Adults 18 to 65, any sex, with IgE-Mediated Hypersensitivity or IgE Mediated Food Allergy. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
To evaluate the ability of cizutamig to reduce IgE levels
Time frame: Baseline to Week 12
Change from baseline in serum IgE
Sponsor's own description
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07408869
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for IgE-Mediated Hypersensitivity
Currently open trials in the same condition.
- NCT07316465 — Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis · NA · recruiting
Other Candid Therapeutics trials
Trials by the same sponsor.
- NCT07052032 — An Open-label Study of CND261 in Seropositive Rheumatoid Arthritis · Phase 1 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07408869 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Candid Therapeutics
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07408869.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing